“A Multicenter, Open Label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005% in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis” (2020) SKIN The Journal of Cutaneous Medicine, 4(5), p. s35. doi:10.25251/skin.4.supp.35.